Attention! Information is for reference only!
Before taking the course, consult a doctor!
WEB SITE ONLY DIRECTORY. NOT PHARMACY! We do not sell medicines! None!

Description of the medicine: Aldesleukin (Aldesleukin)

ALDESLEYKIN (Aldesleukin).

Recombinant (human) analogue of interleukin-2 (obtained using the chain of genes of intoleukin-2 Escherichia coli). Lymphokine.

A protein containing 133 amino acid residues. 125-L-serine-2-133-interleukin-2. C 690 H 1115 N 177 O 203 S 6 (15 600 daltons).

Synonym: Proleukin, Proleukin.

Has immunomodulatory and antitumor effect. As an immunomodulator activates the endogenous defense of the organism, it facilitates the transformation of T-lymphocytes, lymphokine-activated killer cells and tumor-infiltrating lymphocytes into killer cells with antitumor activity. Has an interferonogenic effect - it stimulates the formation of γ-interferon, as well as tumor necrosis factor.

Applied mainly for kidney cancer (with metastases) and melanoma.

Assign intravenous drip at the rate of 1 mg / m 2 per day; Administered as a continuous infusion for 5 days; After a 2-6 day break, repeat the infusion for 5 days (one induction cycle). After 3 weeks, the cycle is repeated. Depending on the effectiveness and tolerance, up to 4 cycles are carried out.

The solution is prepared ex tempore. In the vial with the drug injected with 1.2 ml of water for injection and gently shake it (not shaking) until complete dissolution. For infusions, the resulting solution is diluted in a 5% glucose solution (500 ml). A 0.1% solution of human albumin can be added to the glucose solution.

When the drug is used, various side effects are possible: arterial hypotension, arrhythmias, exacerbation of stenocardia, clotting disorders, thrombosis, oliguria, headache, dyspepsia, pulmonary, liver and kidney disorders, myalgia, arthralgia, convulsive reactions, speech, memory and Sight, thrombocytopenia, leukopenia, anemia, etc. Treatment should be performed under close medical supervision.

Contraindications: far-reaching stages of cancer, multiple metastases, severe cardiovascular diseases, predisposition to convulsive reactions, leukopenia, thrombocytopenia, impaired breathing function, infectious and autoimmune diseases, pregnancy, breast-feeding.

Form release: lyophilized powder for injection solutions in vials of 1.2 mg (18,000,000 IU / kg).

Storage: List A.